EA201490536A1 - Новая кристаллическая форма - Google Patents
Новая кристаллическая формаInfo
- Publication number
- EA201490536A1 EA201490536A1 EA201490536A EA201490536A EA201490536A1 EA 201490536 A1 EA201490536 A1 EA 201490536A1 EA 201490536 A EA201490536 A EA 201490536A EA 201490536 A EA201490536 A EA 201490536A EA 201490536 A1 EA201490536 A1 EA 201490536A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystal form
- new crystal
- new
- compound
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
- Glass Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
Описана новая кристаллическая форма соединения.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530104P | 2011-09-01 | 2011-09-01 | |
| PCT/EP2012/067027 WO2013030374A1 (en) | 2011-09-01 | 2012-08-31 | Novel crystal form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201490536A1 true EA201490536A1 (ru) | 2014-08-29 |
| EA027972B1 EA027972B1 (ru) | 2017-09-29 |
Family
ID=46829730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490536A EA027972B1 (ru) | 2011-09-01 | 2012-08-31 | Новая кристаллическая форма |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US9227953B2 (ru) |
| EP (1) | EP2751094B1 (ru) |
| JP (1) | JP6199291B2 (ru) |
| KR (2) | KR20190075172A (ru) |
| CN (1) | CN103906744A (ru) |
| AU (2) | AU2012300841C1 (ru) |
| BR (1) | BR112014004251A2 (ru) |
| CA (1) | CA2847066C (ru) |
| CL (1) | CL2014000489A1 (ru) |
| CO (1) | CO6890102A2 (ru) |
| CR (1) | CR20140098A (ru) |
| CY (1) | CY1120784T1 (ru) |
| DK (1) | DK2751094T3 (ru) |
| DO (1) | DOP2014000042A (ru) |
| EA (1) | EA027972B1 (ru) |
| ES (1) | ES2686563T3 (ru) |
| HK (1) | HK1198534A1 (ru) |
| HR (1) | HRP20181375T1 (ru) |
| HU (1) | HUE041578T2 (ru) |
| IL (1) | IL230977A (ru) |
| LT (1) | LT2751094T (ru) |
| MA (1) | MA35362B1 (ru) |
| MX (1) | MX349243B (ru) |
| MY (1) | MY172885A (ru) |
| PE (1) | PE20141411A1 (ru) |
| PL (1) | PL2751094T3 (ru) |
| PT (1) | PT2751094T (ru) |
| RS (1) | RS57644B1 (ru) |
| SG (1) | SG2014011886A (ru) |
| SI (1) | SI2751094T1 (ru) |
| UA (1) | UA114607C2 (ru) |
| WO (1) | WO2013030374A1 (ru) |
| ZA (1) | ZA201401176B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141411A1 (es) | 2011-09-01 | 2014-10-29 | Glaxo Group Ltd | Nueva forma de cristal |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| ES2101323T3 (es) | 1992-06-10 | 1997-07-01 | Nanosystems Llc | Nanoparticulas de farmacos antiinflamatorios no esteroideos (nsaid) con superficie modificada. |
| AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| US7741020B2 (en) | 2004-04-16 | 2010-06-22 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
| EA018101B1 (ru) | 2007-05-11 | 2013-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способы лечения кожных язв |
| US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| WO2008140449A1 (en) | 2007-05-11 | 2008-11-20 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| WO2008140450A1 (en) * | 2007-05-11 | 2008-11-20 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| EP2619203A4 (en) | 2010-09-20 | 2014-04-16 | Glaxo Group Ltd | TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF |
| US8637536B2 (en) | 2010-12-06 | 2014-01-28 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
| US8859573B2 (en) | 2010-12-06 | 2014-10-14 | Glaxo Group Limited | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
| ES2847883T3 (es) | 2010-12-17 | 2021-08-04 | Glaxo Group Ltd | Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares |
| PE20141411A1 (es) * | 2011-09-01 | 2014-10-29 | Glaxo Group Ltd | Nueva forma de cristal |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
-
2012
- 2012-08-31 PE PE2014000274A patent/PE20141411A1/es not_active Application Discontinuation
- 2012-08-31 CA CA2847066A patent/CA2847066C/en not_active Expired - Fee Related
- 2012-08-31 BR BR112014004251A patent/BR112014004251A2/pt not_active Application Discontinuation
- 2012-08-31 ES ES12756693.3T patent/ES2686563T3/es active Active
- 2012-08-31 PT PT12756693T patent/PT2751094T/pt unknown
- 2012-08-31 AU AU2012300841A patent/AU2012300841C1/en not_active Ceased
- 2012-08-31 LT LTEP12756693.3T patent/LT2751094T/lt unknown
- 2012-08-31 UA UAA201403151A patent/UA114607C2/uk unknown
- 2012-08-31 US US14/241,913 patent/US9227953B2/en not_active Expired - Fee Related
- 2012-08-31 JP JP2014527685A patent/JP6199291B2/ja not_active Expired - Fee Related
- 2012-08-31 PL PL12756693T patent/PL2751094T3/pl unknown
- 2012-08-31 HU HUE12756693A patent/HUE041578T2/hu unknown
- 2012-08-31 MY MYPI2014700470A patent/MY172885A/en unknown
- 2012-08-31 EA EA201490536A patent/EA027972B1/ru not_active IP Right Cessation
- 2012-08-31 EP EP12756693.3A patent/EP2751094B1/en active Active
- 2012-08-31 SG SG2014011886A patent/SG2014011886A/en unknown
- 2012-08-31 KR KR1020197017797A patent/KR20190075172A/ko not_active Application Discontinuation
- 2012-08-31 SI SI201231371T patent/SI2751094T1/sl unknown
- 2012-08-31 KR KR1020147005011A patent/KR20140056297A/ko not_active Application Discontinuation
- 2012-08-31 WO PCT/EP2012/067027 patent/WO2013030374A1/en active Application Filing
- 2012-08-31 RS RS20181064A patent/RS57644B1/sr unknown
- 2012-08-31 CN CN201280051671.XA patent/CN103906744A/zh active Pending
- 2012-08-31 DK DK12756693.3T patent/DK2751094T3/en active
- 2012-08-31 MX MX2014002454A patent/MX349243B/es active IP Right Grant
-
2014
- 2014-02-13 IL IL230977A patent/IL230977A/en active IP Right Grant
- 2014-02-17 ZA ZA2014/01176A patent/ZA201401176B/en unknown
- 2014-02-27 CL CL2014000489A patent/CL2014000489A1/es unknown
- 2014-02-27 CR CR20140098A patent/CR20140098A/es unknown
- 2014-02-28 MA MA36784A patent/MA35362B1/fr unknown
- 2014-02-28 CO CO14043369A patent/CO6890102A2/es not_active Application Discontinuation
- 2014-02-28 DO DO2014000042A patent/DOP2014000042A/es unknown
- 2014-11-27 HK HK14111997.4A patent/HK1198534A1/xx not_active IP Right Cessation
-
2015
- 2015-11-25 US US14/951,997 patent/US9682074B2/en not_active Expired - Fee Related
-
2016
- 2016-01-28 AU AU2016200492A patent/AU2016200492B2/en not_active Ceased
- 2016-09-01 US US15/254,160 patent/US9694004B2/en not_active Expired - Fee Related
-
2018
- 2018-08-28 HR HRP20181375TT patent/HRP20181375T1/hr unknown
- 2018-09-04 CY CY181100922T patent/CY1120784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20140024A (es) | Compuestos inhibidores de metaloenzimas | |
| BR112013028235A2 (pt) | refrigerador | |
| CR20140042A (es) | Indazoles | |
| BR112013032344A2 (pt) | método para a fabricação de aparelhos ortodônticos transparentes | |
| CR20130539A (es) | Triazolopiridinas | |
| CR20150061A (es) | Compuesto de pirazolopirimidinas | |
| BR112013028512A2 (pt) | cápsula | |
| UY33930A (es) | Inhibidores novedosos de quinasas | |
| DK2678329T3 (da) | Triazolopyridinforbindelser som pim-kinase-hæmmere | |
| CR20130419A (es) | Derivados heterocíclicos de amina | |
| CO6910197A2 (es) | Compuestos novedosos | |
| CR20120637A (es) | Triazolopiridinas sustituidas | |
| LTPA2020526I1 (lt) | 2-Acilaminotiazolo junginio kristalai | |
| EA201690894A1 (ru) | Феноксиэтилы | |
| CR20140094A (es) | Derivados de etinilo | |
| CR20150084A (es) | 2-oxo-2,3-dihidro-indoles | |
| BR112013032555A2 (pt) | composição selante híbrida | |
| UY33864A (es) | Novedoso Derivado Cristalino de Oxazina | |
| IN2014DN06192A (ru) | ||
| CR20130597A (es) | Isoxazolinas como agentes terapèuticos | |
| CO6761304A2 (es) | Nuevos compuestos de bezodioxol-piperazina | |
| EA201201667A1 (ru) | Способ получения l-аргининовой соли периндоприла | |
| CY1121116T1 (el) | Νεα μεθοδος για την συνθεση αγομελατινης | |
| EA201491446A1 (ru) | Способы получения пиперазинового пролекарства - ингибитора прикрепления вич | |
| CY1120784T1 (el) | Νεα κρυσταλλικη μορφη |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |